Lenvatinib Shows Positive Results in Clinical Trial08/2014
July 30, 2014— Lenvatinib, a new drug that has shown promise in a clinical trial for treating progressive differentiated thyroid cancer (papillary, follicular, and their variants) that does not respond to radioactive iodine, will receive accelerated assessment by the European Medicines Agency (EMA).
Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor. It is manufactured by Eisai.
Esai also reported that it soon plans to submit an application to the United States Food and Drug Administration (FDA) for Lenvantinib.
* * * * *
Lenvatinib shows promising results as a treatment option for people with differentiated radioiodine-resistant thyroid cancer, according to a Phase III clinical trial reported at the meeting of the American Society of Clinical Oncology (ASCO).
Lead study author is Martin Schlumberger, M.D., Oncology Professor at University Paris Sud, France and ThyCa Medical Advisor.
A summary of the presentation at ASCO is here.